Pharmaceutical regulation in China follows the product across its full lifecycle: research, nonclinical and clinical work, registration, manufacturing, release, distribution, online sales, promotion, pharmacovigilance, post-market evaluation and recall. The first task is to classify the product and intended claim, identify the marketing authorization holder and each licensed operator, and record the exact regulatory event or deadline.
The revised Drug Administration Law Implementation Regulations took effect on May 15, 2026. Companies should therefore check current requirements rather than relying on pre-revision summaries. Preserve registration dossiers, licences, quality agreements, batch and distribution records, safety data, promotional approvals, complaints, recall assessments and every inspection document. This guide provides national orientation and does not determine a product's classification or approval route.
Subject to editorial and legal review. Obtain product-specific advice where a clinical hold, serious safety signal, inspection finding, recall, counterfeit concern or regulatory deadline is active.
Classify the product, claim and responsible parties
Determine whether the item is a drug, vaccine, medical device, cosmetic, health food, medical-institution preparation or another regulated product. Classification follows composition, intended use, mechanism, presentation and claims, not the seller's label alone. Build a responsibility map covering the applicant, marketing authorization holder (MAH), domestic responsible person where relevant, research organizations, contract manufacturers, testing laboratories, importers, distributors, online platforms and medical institutions.
The 2026 implementation regulations
The revised regulations contain 89 articles and apply from May 15, 2026. They refine research and registration procedures, accelerated routes and re-registration; add market exclusivity for qualifying pediatric and rare-disease drugs and data protection for specified products; detail MAH duties; address cross-border manufacture; strengthen full-chain quality supervision; and require post-market evaluation and risk action. Identify whether a legacy approval, pending application or current operation is affected by a transitional or updated rule.
Research, clinical trials and registration
Document the sponsor, investigational product, nonclinical basis, ethics review, informed-consent process, trial registration, sites, investigators, safety reporting and data integrity controls. Registration strategy should identify product category, proposed indication, technical standards, sample testing, inspection or verification exposure and any accelerated pathway. Changes during development must be assessed before implementation rather than reconstructed at filing.
MAH and manufacturing controls
The MAH bears lifecycle responsibility for safety, efficacy and quality and cannot outsource accountability through a manufacturing or quality agreement. Map the authorized product, approved sites and process, suppliers, entrusted-manufacturing arrangements, release responsibilities, deviations, change control and traceability. Drugs manufactured outside China for the Chinese market must comply with the Drug Administration Law, the revised regulations, standards and applicable quality rules, and may be subject to overseas inspection.
Distribution, use and online sales
Verify manufacturing and distribution licences, approved business modes and scope, supplier and customer qualification, receipt and acceptance, storage, temperature, transport and traceability. Online sellers must operate within their qualifications; prescription sources must be authentic and reliable, prescription-drug sales require real-name and review controls, and specially controlled products cannot be sold online. Platforms have verification, monitoring and stop-service duties for serious violations.
Promotion and product information
Keep labels, package inserts, websites, patient materials, healthcare-professional communications, conference activity and distributor content aligned with the approved product information and advertising rules. Separate scientific exchange, patient support and commercial promotion in policy and evidence. Review disease-awareness and digital content for implied product claims, and control benefits or hospitality provided to healthcare institutions and professionals under pharmaceutical, advertising, anti-unfair-competition and criminal rules.
Pharmacovigilance, evaluation and recall
Maintain systems for adverse-reaction collection, assessment and reporting, aggregate safety review, risk-management measures, complaints, quality defects and escalation. Under the revised regulations, the MAH must periodically evaluate marketed drugs and take measures supported by the risk-benefit assessment, which may include revising instructions, raising standards, improving processes, suspending production or sales, recalling product or seeking cancellation of the registration certificate. Document the decision path and affected batches.
Inspections, enforcement and response
Prepare an accurate facility and product scope, preserve raw data and electronic audit trails, identify each request and response, and distinguish observation, corrective order, sampling result and final decision. Potential consequences include warnings, correction, confiscation, fines, suspension, licence or registration consequences, debarment or personal restrictions, civil liability and criminal referral. Do not delete data, backdate records, release quarantined product or obstruct inspection.
Working-file checklist
- Product classification, claims, approval number and current status.
- MAH, responsible person and licensed supply-chain map.
- Research, ethics, trial and registration records.
- Manufacturing sites, quality agreements, batches and change controls.
- Distribution, storage, transport and traceability evidence.
- Labels, inserts, promotion and online-sales controls.
- Safety signals, complaints, evaluation and recall decisions.
- Inspection records, CAPA plan and review deadlines.
Official sources
- Drug Administration Law
- 2026 Drug Administration Law Implementation Regulations
- NMPA drug registration inspection service and legal basis
- NMPA online drug sales provisions
Law checked: September 11, 2026. Official Chinese texts control. Confirm product classification, approval status, MAH responsibility, supply chain and the current regulatory event before acting.
